“Breast cancer death rates declined almost 40 percent between 1989 and 2015, averting 322,600 deaths, the American Cancer Society reportedTuesday.
“Breast cancer death rates increased by 0.4 percent per year from 1975 to 1989, according to the study. After that, mortality rates decreased rapidly, for a 39 percent drop overall through 2015. The report, the latest to document a long-term reduction in breast-cancer mortality, attributed the declines to both improvements in treatments and to early detection by mammography.”
“The latest annual report from the American Cancer Society shows that death rates from cancer in the US are continuing to fall, ‘giving reasons to celebrate but not to stop,’ according to the voluntary health organization whose goal is the eradication of cancer.
“In figures to be published in CA: A Cancer Journal for Clinicians, the American Cancer Society (ACS) show how the death rate from cancer in the US has dropped by 22% since its peak in 1991.
“They say this means about 1.5 million deaths from cancer have been avoided in the last 20 years.
“The ACS estimate that in 2015, the US will see a total of 1,658,370 new cancer cases and 589,430 deaths due to the disease.
“Cancer was responsible for nearly 1 in 4 deaths in the US in 2011, making it the second leading cause of death overall -close behind heart disease.”
Callahan, M, Rampal, R ... Levine, RL, Chapman, PB. NEJM. Dec. 13, 2013.
Vemurafenib, a selective RAF inhibitor, extends survival among patients with BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–mutant cells but activates ERK signaling in BRAF wild-type cells. This paradoxical activation of ERK signaling is the mechanistic basis for the development of RAS-mutant squamous-cell skin cancers in patients treated with RAF inhibitors. This study reports the accelerated growth of a previously unsuspected RAS-mutant leukemia in a patient with melanoma who was receiving vemurafenib. Exposure to vemurafenib induced hyperactivation of ERK signaling and proliferation of the leukemic cell population, an effect that was reversed on drug withdrawal.